German China

UK: Attacking Sars-Cov-2's Main Protease Covid-19: Novel Approach Uses Fragment Screening to Accelerate Antiviral Development

Editor: MA Alexander Stark

A new paper in Nature Communications outlines how an international research team has identified potential ways forward to rapidly design improved and more potent compounds in the fight against Covid-19.  The work is the result of a massive fragment screening effort to develop an antiviral targeting the Sars-Cov-2 main protease.

Structure of Sars-Cov-2 Main protease. Cartoon representation of the Covid-19 dimer with a semi-transparent surface in green and orange delineating each monomer.
Structure of Sars-Cov-2 Main protease. Cartoon representation of the Covid-19 dimer with a semi-transparent surface in green and orange delineating each monomer.
(Source: Diamond Light Source)

Harwall/UK — Covid-19, caused by Sars-Cov-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, Sars-Cov-1 or Mers-Cov, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, a team at Diamond Light Source performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the Sars-Cov-2 main protease, one of two cysteine viral proteases essential for viral replication. Their crystallographic screen identified 74 hits that span the entire active site, as well as three hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors and offer unprecedented structural and reactivity information for on-going structure-based drug design against Sars-Cov-2 main protease. The project was led by Martin Walsh, Deputy Life Sciences Director at Diamond Light Source; Frank von Delft, Professor of Structural Chemical Biology at the University of Oxford and Principal Beamline Scientist of I04-1/XChem at Diamond; and Nir London, Assistant Professor at the Weizmann Institute Israel.

For this study, called Crystallographic and electrophilic fragment screening of the Sars-Cov-2 main protease, the team probed an essential enzyme of Sars-Cov-2 with over 1,250 unique small compound, termed fragments, and identified 74 high-value fragment hits which can be used to develop new inhibitors for this essential viral protein. The paper details the data along with proposed design routes for progressing towards improved, more potent, compounds.


Structural biology, which can play a key role in drug development, was also rapidly deployed after the 2002 Sars-Cov-1 outbreak, with earlier work by the Hilgenfeld group on the main protease of coronarviruses leading to crystal structures of Sars-Cov-1 protease and inhibitor complexes. Other studies have taken the popular approach of a high-throughput screens (HTS) using very large compound libraries, followed by structural studies to elucidate the binding mode. 

Martin Walsh, who is addition to his role at Diamond is also a Medical Research Council (MRC) funded Research Group Leader at the Research Complex at Harwell (RCaH), said that despite these efforts, drugs remained elusive that directly target Sars-Cov-2 (rather than disease symptoms) and were verified by clinical trials. “In retrospect, this is perhaps unsurprising for the main protease inhibitors, as both peptidomimetic and covalent inhibition carry risks as strategies for drug development; in general, the simpler the molecule the lower the risk. We, therefore, applied a different approach to this protease, using fragment screening by high-throughput structural biology”, he added.

Funded by Crowdsourcing Initiative

Fragment methods have become a staple of modern drug discovery, using small collections (100 s or 1000 s) of small compounds (<300 Da) that bind promiscuously and thus sample a far larger chemical space than is achieved by HTS. The challenge is that the very weak binding of fragment hits requires highly sensitive biophysical detection, careful confirmation of binding and specialised medicinal chemistry expertise take the hits and develop them into fully potent drug candidates. However, the real promise of fragments with the right expertise and equipment, they can quickly and efficiently be converted into valid drug candidates with a much simpler route to clinical impact.

Rapid advances in technology and automation at synchrotron radiation sources has made screening directly in crystal structures routinely possible at facilities like the XChem platform at Diamond Light Source. The team took the highly unusual route of releasing all the experimental data as soon as it was generated; the announcement on social media triggered a large international collaboration that harnessed the combined knowledge of scientists worldwide through a novel crowdsourcing initiative that they called Covid Moonshot.

Frank von Delft, said: “Performing the experiment and achieving the high data quality in a few weeks, as lockdown started, was a tour de force, and a credit to our highly talented scientists. Even more remarkable was the response of the international community to the data release: it mobilised a vast pool of expertise, technologies and philanthropy, which evolved into a unique and rigorous drug discovery effort that aims to develop rapidly an entirely novel, easily synthesised, oral antiviral with good safety and pre-clinical properties. Working fully in the open, data are released near real-time, so the outcome will be available to any drugs manufacturer world-wide.”

Related Publication: M.A. Walsh et el. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease Nature Communications. DOI: 10.1038/s41467-020-18709-w.